secwatch.observer — SEC 8-K summary
======================================

Issuer:     KALA BIO, Inc. (KALA)
CIK:        0001479419
Form:       8-K
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001558370-25-004080
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KALA BIO posts Q4 net loss of $8.2M; Phase 2b topline data delayed to 3Q25
--------------------------------------------------------------------------

- Randomized 87 patients in Phase 2b CHASE trial for KPI-012; extending enrollment due to 13 unverified patients; topline data now expected in 3Q25.
- Raised $10.75M in December private placement with SR One, Cormorant, Woodline.
- Cash and equivalents $51.2M at year-end; expected to fund operations into 1Q26.
- Q4 operating loss $9.5M; net loss $8.2M ($1.74/share).
- Full year 2024 net loss $38.5M ($10.15/share); no revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/0001558370-25-004080-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479419/000155837025004080/kala-20250331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-004080

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer